JP2002540164A5 - - Google Patents

Download PDF

Info

Publication number
JP2002540164A5
JP2002540164A5 JP2000607650A JP2000607650A JP2002540164A5 JP 2002540164 A5 JP2002540164 A5 JP 2002540164A5 JP 2000607650 A JP2000607650 A JP 2000607650A JP 2000607650 A JP2000607650 A JP 2000607650A JP 2002540164 A5 JP2002540164 A5 JP 2002540164A5
Authority
JP
Japan
Prior art keywords
rarβ2
agonist
pharmaceutical composition
neurites
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000607650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002540164A (ja
Filing date
Publication date
Priority claimed from GBGB9907461.9A external-priority patent/GB9907461D0/en
Application filed filed Critical
Publication of JP2002540164A publication Critical patent/JP2002540164A/ja
Publication of JP2002540164A5 publication Critical patent/JP2002540164A5/ja
Pending legal-status Critical Current

Links

JP2000607650A 1999-03-31 2000-03-30 因 子 Pending JP2002540164A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9907461.9 1999-03-31
GBGB9907461.9A GB9907461D0 (en) 1999-03-31 1999-03-31 Neurite regeneration
PCT/GB2000/001211 WO2000057900A2 (en) 1999-03-31 2000-03-30 Factor for regulation of neurite growth

Publications (2)

Publication Number Publication Date
JP2002540164A JP2002540164A (ja) 2002-11-26
JP2002540164A5 true JP2002540164A5 (https=) 2007-05-17

Family

ID=10850746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000607650A Pending JP2002540164A (ja) 1999-03-31 2000-03-30 因 子

Country Status (11)

Country Link
US (2) US20070054961A1 (https=)
EP (2) EP1180039B1 (https=)
JP (1) JP2002540164A (https=)
KR (1) KR20010104401A (https=)
CN (1) CN100350970C (https=)
AT (1) ATE342728T1 (https=)
AU (1) AU770394B2 (https=)
CA (1) CA2369009A1 (https=)
DE (1) DE60031396T2 (https=)
GB (2) GB9907461D0 (https=)
WO (1) WO2000057900A2 (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003533184A (ja) * 2000-03-30 2003-11-11 オックスフォード バイオメディカ(ユーケイ)リミテッド レチノイン酸レセプターβ2、そのアンタゴニスト、および神経障害治療用の遺伝子治療ベクター
GB0103998D0 (en) * 2001-02-19 2001-04-04 King S College London Method
WO2004072443A1 (en) 2003-02-11 2004-08-26 Statoil Asa Efficient combined cycle power plant with co2 capture and a combustor arrangement with separate flows
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
MX374532B (es) 2013-06-17 2025-03-06 Broad Inst Inc Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
RU2716420C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
CN105683379A (zh) 2013-06-17 2016-06-15 布罗德研究所有限公司 用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
SG10201804975PA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
JP6712948B2 (ja) 2013-12-12 2020-06-24 ザ・ブロード・インスティテュート・インコーポレイテッド 組成物、及びヌクレオチドリピート障害におけるcrispr−cas系の使用方法
JP7103750B2 (ja) 2013-12-12 2022-07-20 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのCRISPR-Cas系及び組成物の送達、使用及び治療適用
EP3080259B1 (en) 2013-12-12 2023-02-01 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
WO2016028682A1 (en) 2014-08-17 2016-02-25 The Broad Institute Inc. Genome editing using cas9 nickases
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
JP6596090B2 (ja) 2014-12-17 2019-10-23 キングス カレッジ ロンドン レチノイン酸受容体ベータ(RARβ)アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物
EP3234192B1 (en) 2014-12-19 2021-07-14 The Broad Institute, Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
EP3822291A1 (en) 2015-06-10 2021-05-19 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
AU2016279077A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
TWI906646B (zh) 2015-06-18 2025-12-01 美商博得學院股份有限公司 降低脫靶效應的crispr酶突變
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
WO2017031370A1 (en) 2015-08-18 2017-02-23 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CN116814590A (zh) 2015-10-22 2023-09-29 布罗德研究所有限公司 Vi-b型crispr酶和系统
EP3368687B1 (en) 2015-10-27 2021-09-29 The Broad Institute, Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
US12110490B2 (en) 2015-12-18 2024-10-08 The Broad Institute, Inc. CRISPR enzymes and systems
KR20260004568A (ko) 2016-04-19 2026-01-08 더 브로드 인스티튜트, 인코퍼레이티드 신규한 crispr 효소 및 시스템
EP3445853A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
AU2017257274B2 (en) 2016-04-19 2023-07-13 Massachusetts Institute Of Technology Novel CRISPR enzymes and systems
CN109642231A (zh) 2016-06-17 2019-04-16 博德研究所 Vi型crispr直向同源物和系统
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
US12595478B2 (en) 2016-06-29 2026-04-07 The Broad Institute, Inc. Crispr-Cas systems having destabilization domain
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
EP4485466A3 (en) 2016-08-17 2025-04-02 The Broad Institute Inc. Novel crispr enzymes and systems
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
US12499971B2 (en) 2016-09-28 2025-12-16 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
CA3052099A1 (en) 2017-01-30 2018-08-02 Mathias LABS Repair template linkage to endonucleases for genome engineering
JP2020511141A (ja) 2017-03-15 2020-04-16 ザ・ブロード・インスティテュート・インコーポレイテッド 新規Cas13bオルソログCRISPR酵素及び系
AU2018251801B2 (en) 2017-04-12 2024-11-07 Massachusetts Institute Of Technology Novel type VI CRISPR orthologs and systems
WO2018191750A2 (en) 2017-04-14 2018-10-18 The Broad Institute Inc. Novel delivery of large payloads
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
WO2018213726A1 (en) 2017-05-18 2018-11-22 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
US12415000B2 (en) 2017-07-07 2025-09-16 The Broad Institute, Inc. CRISPR system based antiviral therapy
AU2018338318B2 (en) 2017-09-21 2022-12-22 Massachusetts Institute Of Technology Systems, methods, and compositions for targeted nucleic acid editing
WO2019071054A1 (en) 2017-10-04 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS
WO2019135816A2 (en) 2017-10-23 2019-07-11 The Broad Institute, Inc. Novel nucleic acid modifiers
WO2019089803A1 (en) 2017-10-31 2019-05-09 The Broad Institute, Inc. Methods and compositions for studying cell evolution
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
US12221720B2 (en) 2017-11-13 2025-02-11 The Broad Institute, Inc. Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
WO2019126709A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted dna base editing
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
JP2021532815A (ja) 2018-08-07 2021-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 新規Cas12b酵素およびシステム
US12421507B2 (en) 2018-08-20 2025-09-23 The Broad Institute, Inc. Methods and compositions for optochemical control of CRISPR-CAS9
CN113544266A (zh) 2018-12-17 2021-10-22 博德研究所 Crispr相关转座酶系统和其使用方法
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
US12534714B2 (en) 2019-03-18 2026-01-27 The Broad Institute, Inc. Type VII CRISPR proteins and systems
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
GB201907647D0 (en) * 2019-05-30 2019-07-17 King S College London Therapeutic methods
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
IL316038A (en) 2022-04-04 2024-11-01 Univ California Preparations and methods for genetic complementation
WO2025072383A1 (en) 2023-09-25 2025-04-03 The Broad Institute, Inc. Viral open reading frames, uses thereof, and methods of detecting the same
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025250808A1 (en) 2024-05-29 2025-12-04 The Brigham And Women’S Hospital, Inc. Anti-crispr delivery compositions and methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
JPS59501572A (ja) 1982-05-19 1984-09-06 ユニリーバー ナームローゼ ベンノートシヤープ クルイベロミセス属酵母およびその製造法
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
DE3480411D1 (en) 1983-07-06 1989-12-14 Gist Brocades Nv Molecular cloning and expression in industrial microorganism species
US4885249A (en) 1984-12-05 1989-12-05 Allelix, Inc. Aspergillus niger transformation system
ATE253119T1 (de) 1985-04-15 2003-11-15 Dsm Ip Assets Bv Verwendung des glucoamylasepromotors aus apergillus
NO872932L (no) 1986-07-18 1988-01-19 Gist Brocades Nv Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
US4808630A (en) * 1987-01-16 1989-02-28 United States Of America Method of treating psychotic illnesses
JPS63188622A (ja) * 1987-01-16 1988-08-04 アメリカ合衆国 精神病治療薬
AR247761A1 (es) 1987-07-28 1995-03-31 Gist Brocades Nv Metodo para producir un polipeptido en una celula hospedante de kluyveromyces, dicha celula hospedante transformada y secuencia a adn empleada
KR100225087B1 (ko) 1990-03-23 1999-10-15 한스 발터라벤 피타아제의 식물내 발현
CA2211142A1 (en) * 1995-01-23 1996-08-01 Ligand Pharmaceuticals Incorporated Human retinoid x receptor - gamma (hrxr-gamma)
IT1276459B1 (it) * 1995-06-30 1997-10-31 Khodor Ammar Composizioni cosmetiche con proprieta' antimicotiche, efficaci contro la psoriasi e la caduta dei capelli e metodo cosmetico per la
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
AU6897498A (en) 1997-04-25 1998-11-24 American Home Products Corporation Human neuronal cell line
EP1027059A2 (en) * 1997-10-27 2000-08-16 Curis, Inc. Enhancement of morphogen activity

Similar Documents

Publication Publication Date Title
JP2002540164A5 (https=)
DZ2639A1 (fr) Composés thérapeutiquement actifs basés sur le remplacement bio-isostérique du catéchol par l'indazole dans des inhibiteurs de PDE4 leur procédé de production et compositions pharmaceutiques les contenant.
HUP0003121A3 (en) Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
MA26508A1 (fr) Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation.
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
NZ514574A (en) Novel method of treatment
EE04576B1 (et) Suposiit happes ebapüsivate toimeainete tarbeks, selle valmistamismeetod, toimeaineühik ja selle valmistamismeetod ning preparaat
MXPA02010550A (es) Agonistas muscarinicos.
EE200100275A (et) Kristalsesse olekusse konverteeritud amorfse ja/või metastabiilse kristalse piirkonnaga osakeste valmistamismeetod
DE59908764D1 (de) Agitationsunabhängige pharmazeutische multiple-unit-retardzubereitungen und verfahren zu ihrer herstellung
WO2003096989A3 (en) Anti tubercular drug: compositions and methods
ZA967880B (en) Compositions and methods for inhibition of the patho-physiologic actions in mammals in tumor necrosis facto-alpha
YU186791A (sh) Nove farmaceutske formulacije koje sadrže farmaceutski aktivnu jonizujuću supstancu, kao i postupak za njihovo dobijanje
SE0001914L (sv) Förbättring av Peyronies sjukdom
DE60301570D1 (de) 1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ATE269057T1 (de) Arzneizubereitungen und deren herstellungsverfahren
JP2002501941A5 (https=)
ATE247645T1 (de) Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung
BR0104345A (pt) Tratamento combinado para a depressão e ansiedade
WO2002007716A3 (en) Method for treating angina
BR0008739A (pt) Composições de liberação controlada debeta-histina
JP2002536328A5 (https=)
FR2793490B1 (fr) Procede de preparation du (1r,2s,4r)-(-)-2-[(2'-{n,n- dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]- bicyclo[2.2.1]-heptane et ses sels d'addition d'acide pharmaceutiquement acceptables